netFormulary The Pennine Acute Hospitals NHS
NHS Trust Formulary  
 Formulary Chapter 6: Endocrine system - Full Chapter
Chapter Links...
 Details...  Expand sub section  Short-acting insulins  Expand sub section  Soluble Insulin  Expand sub section  Rapid Acting Insulin Analogues
Apidra (Insulin Glulisine)
View adult BNF View SPC online View childrens BNF  Track Changes
First Choice 3ml cartridge (via ClikSTAR or Autopen 24)
3ml pre-filled disposable pen (SoloStar)
Humalog (Insulin Lispro)
View adult BNF View SPC online View childrens BNF  Track Changes
First Choice 3ml cartridge (via Autopen Classic or HumaPen)
3ml prefilled disposable pen (Kwikpen)
NovoRapid (Insulin Aspart)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary 3ml cartridge (via Novopen devices)
3ml prefilled disposable pen (Flexpen)
Fiasp (Insulin Aspart)
View adult BNF View SPC online View childrens BNF  Track Changes

3ml cartridge (via Novopen® devices)
3ml prefilled disposable pen (FlexTouch®)

Restricted Item As per GMMMG - for type 1 diabetics who:

  • are planning or actively pregnant, or

  • have post prandial glucose readings of >10mmol at 2 hours

note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Track Changes
Display tracking information
click to search
Link to adult BNF
click to search
Link to children's BNF
click to search
Link to SPCs
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHS England

Traffic Light Status Information

Status Description


Drugs designated amber are suitable for shared care arrangements under a shared care protocol. Prescribing may be transferred from secondary to primary care once the patient is stabilised and agreed shared care arrangements have been established. Alternatively primary care may initiate under the supervision of secondary care if this option is given in the shared care document. It is recommended that shared care arrangements should be drawn up following local discussion and agreement by prescribing parties.   


These products have been reviewed by the GM Joint Formulary Group and have been deemed not suitable for prescribing for adults in primary or secondary care within Greater Manchester. These decisions have been made on the basis of safety, efficacy and cost-effectiveness of the products.  


Not used   

Green 1

Drugs designated green1 are suitable for initiation and ongoing prescribing within primary care.   

Green 2

Drugs designated green2 can be initiated by primary care following written or verbal advice from a specialist and then be subsequently safely prescribed in primary care with little or no monitoring required.  

Green 3

Drugs designated green3 are suitable for on-going prescribing within primary care after specialist initiation and an initial review (unless specified) in secondary care. Little or no monitoring is required.  


Not suitable for routine prescribing but may be suitable for a defined patient population. Whilst prescribers should think very carefully before prescribing or recommending any of the products on the grey list, there may be exceptional instances when the use of one of these products is necessary for a particular patient.   


Drugs designated red are considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy, this may include arranging for supply via a home care company.